EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry

D Armenia, G Marchegiani, V Spagnuolo iD, M C Bellocchi, L Galli, T Clemente iD, L Carioti, R Lolatto, M Ferrara, R Gagliardini, G C Marchetti iD, C Torti und 6 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von D Armenia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departimental Faculty, Saint Camillus International University of Health Sciences, Rome, Italy. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Anti-HIV Agents, Drug Resistance, Viral. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare, Gilead Sciences, MSD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to clarify whether resistance detected in HIV-1 DNA might evolve in virologically suppressed highly treatment-experienced (HTE) individuals with multidrug resistance (MDR).

Methods

Twenty-three virologically suppressed HTE MDR individuals from the PRESTIGIO Registry with two longitudinal samples available under virological suppression at two different time points (T0−T1) were analysed. HIV-1 DNA levels were quantified using droplet digital PCR, and resistance was assessed through next-generation sequencing (NGS) set at 5%. Mutational load was also evaluated.

Results

At T0, individuals had been virologically suppressed for a median time of 3 years (IQR 3–5) under a salvage regimen, mostly containing dolutegravir (95.7%) and/or darunavir (69.6%). The median HIV-1 DNA level was 2588 copies/106 CD4+ cells at T0 and remained stable at T1 (2322 copies/106 CD4+ cells; P = 0.831). Individuals with at least ≥3-class resistance in HIV-1 DNA were 20 (87.0%) at T0 and 18 (78.2%) at T1 (P = 0.607). In those receiving NNRTI-sparing treatment (52.2%), the number of NNRTI major resistance mutation (MRM) significantly decreased over time (T0, 2 [1–3]; T1, 0 [0–1]; P = 0.027). No significant temporal differences in the number of PI, NRTI and integrase strand transfer inhibitor (INSTI) MRM were found. Specific MRM, such as M184V, decreased over time, particularly in individuals who were receiving a 3TC-/FTC-sparing salvage regimen or with a T0 mutational load of <1000 copies/106 CD4+ cells.

Conclusions

Over a year, HIV-1 DNA MRM generally remained unchanged in suppressed HTE MDR people with HIV (PWH) except for a significant decline in M184V and a reduction of NNRTI resistance in the absence of NNRTI pressure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsAnti-HIV AgentsDrug Resistance, ViralDNA, ViralDrug Resistance, Multiple, ViralEvolution, MolecularHumansLongitudinal StudiesMaleFemaleAdultMiddle AgedAntiretroviral Therapy, Highly ActiveViral LoadRegistriesHigh-Throughput Nucleotide SequencingMutationPiperazinesCD4 Lymphocyte Count

Substanzen

Anti-HIV AgentsDNA, ViralPiperazines

Autor:innen und Institutionen

  • Departimental Faculty, Saint Camillus International University of Health Sciences, Rome, Italy.
  • Department of Experimental Medicine, University of Rome 'Tor Vergata', Via Montpellier 1, Rome 00133, Italy.
  • Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Medical Sciences, Unit of Infectious Diseases, University of Torino, Torino, Italy.
  • Clinical Infectious Diseases Department, National Institute for Infectious Diseases 'L. Spallanzani' IRCCS, Rome, Italy.
  • Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy.

ORCID-Profile: V Spagnuolo, T Clemente, G C Marchetti, M Zazzi, A Castagna

Förderung

  • ViiV Healthcare
  • Gilead Sciences
  • MSD
  • Janssen-Cilag

Zitieren

APA

Armenia, D., Marchegiani, G., Spagnuolo, V., Bellocchi, M. C., Galli, L., Clemente, T., Carioti, L., Lolatto, R., Ferrara, M., Gagliardini, R., Marchetti, G. C., Torti, C., De Socio, G., Fornabaio, C., Zazzi, M., Castagna, A., Santoro, M. M., & PRESTIGIO Study Group (2025). Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf349

Vancouver

Armenia D, Marchegiani G, Spagnuolo V, Bellocchi MC, Galli L, Clemente T, et al. Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf349

BibTeX
@article{Armenia2025,
  author = {Armenia, D and Marchegiani, G and Spagnuolo, V and Bellocchi, M C and Galli, L and Clemente, T and Carioti, L and Lolatto, R and Ferrara, M and Gagliardini, R and Marchetti, G C and Torti, C and De Socio, G and Fornabaio, C and Zazzi, M and Castagna, A and Santoro, M M and PRESTIGIO Study Group, PRESTIGIO Study Group},
  title = {Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf349}
}
Kostenlos starten →